Unknown

Dataset Information

0

Antitumor activity of the aurora a selective kinase inhibitor, alisertib, against preclinical models of colorectal cancer.


ABSTRACT:

Background

The Aurora kinases are a family of serine/threonine kinases comprised of Aurora A, B, and C which execute critical steps in mitotic and meiotic progression. Alisertib (MLN8237) is an investigational Aurora A selective inhibitor that has demonstrated activity against a wide variety of tumor types in vitro and in vivo, including CRC.

Results

CRC cell lines demonstrated varying sensitivity to alisertib with IC50 values ranging from 0.06 to > 5 umol/L. Following exposure to alisertib we observed a decrease in pAurora A, B and C in four CRC cell lines. We also observed an increase in p53 and p21 in a sensitive p53 wildtype cell line in contrast to the p53 mutant cell line or the resistant cell lines. The addition of alisertib to standard CRC treatments demonstrated improvement over single agent arms; however, the benefit was largely less than additive, but not antagonistic.

Methods

Forty-seven CRC cell lines were exposed to alisertib and IC50s were calculated. Twenty-one PDX models were treated with alisertib and the Tumor Growth Inhibition Index was assessed. Additionally, 5 KRAS wildtype and mutant PDX models were treated with alisertib as single agent or in combination with cetuximab or irinotecan, respectively.

Conclusion

Alisertib demonstrated anti-proliferative effects against CRC cell lines and PDX models. Our data suggest that the addition of alisertib to standard therapies in colorectal cancer if pursued clinically, will require further investigation of patient selection strategies and these combinations may facilitate future clinical studies.

SUBMITTER: Pitts TM 

PROVIDER: S-EPMC5226583 | biostudies-literature | 2016 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications


<h4>Background</h4>The Aurora kinases are a family of serine/threonine kinases comprised of Aurora A, B, and C which execute critical steps in mitotic and meiotic progression. Alisertib (MLN8237) is an investigational Aurora A selective inhibitor that has demonstrated activity against a wide variety of tumor types in vitro and in vivo, including CRC.<h4>Results</h4>CRC cell lines demonstrated varying sensitivity to alisertib with IC50 values ranging from 0.06 to > 5 umol/L. Following exposure to  ...[more]

Similar Datasets

| S-EPMC3215888 | biostudies-literature
| S-EPMC3524359 | biostudies-literature
| S-EPMC6401337 | biostudies-literature
| S-EPMC7864382 | biostudies-literature
| S-EPMC3867644 | biostudies-literature
| S-EPMC4547019 | biostudies-literature
| S-EPMC4468408 | biostudies-literature
| S-EPMC3537923 | biostudies-literature
| S-EPMC6982547 | biostudies-literature
| S-EPMC5869873 | biostudies-literature